Scynexis (NASDAQ: SCYX) is a clinical stage biotech company based out of New Jersey. The company has one significant drug under development in multiple indications, ibrexafungerp, for the treatment of … [Read more...] about In a Tough Environment for Biotechs, Can the Science at Scynexis Win?
ibrexafungrep
Interview with SCYNEXIS Following Positive Interim-Results from Phase 3 Open-Label FURI Study
Preface The following was the result of discussion and collaboration between MS Money Moves and SCYNEXIS (Nasdaq: SCYX) Chief Financial Officer Eric Francois. We are thankful for his time and … [Read more...] about Interview with SCYNEXIS Following Positive Interim-Results from Phase 3 Open-Label FURI Study
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Japanese
Portuguese
Russian
Spanish